https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / Melanoma Manag 2019 May;6(2):MMT20
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / Melanoma Manag 2019 May;6(2):MMT202019-05-31 00:00:002019-05-31 00:00:00Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17032)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17032)2019-05-31 00:00:002019-05-31 00:00:00A phase I trial evaluating the safety and efficacy of weekly paclitaxel or cisplatin with electro-hyperthermia in patients with recurrent or persistent epithelial ovarian, fallopian tubal or primary peritoneal carcinoma (KGOG 3030).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e14212)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e14212)2019-05-31 00:00:002019-05-31 00:00:00Possible viral oncolysis by members of the Reoviridae and Paramyxoviridae families (an in vitro study).
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17005)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17005)2019-05-31 00:00:002019-05-31 00:00:00Dynamics of the immune status in patients with cervical cancer receiving complex treatment with dendritic cell vaccine.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e20674)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e20674)2019-05-31 00:00:002019-05-31 00:00:00Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15783)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15783)2019-05-31 00:00:002019-05-31 00:00:00Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15748)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15748)2019-05-31 00:00:002020-05-06 15:03:38Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21025)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21025)2019-05-31 00:00:002020-05-06 15:06:09Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21024)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21024)2019-05-31 00:00:002020-05-06 15:04:34Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2019-05-29 / Front Oncol 2019;9:436
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2019-05-29 / Front Oncol 2019;9:4362019-05-29 00:00:002022-09-29 14:03:17STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
